Gene polymorphisms in renal transplantation

Seminars in Nephrology

Volumn 30, Issue 4, 2010, Pages 418-425

  Grafals, Monica ^a   Kamal, Leila ^b   Chung, Daniel ^c   Abdi, Reza ^d  

^a TUFTS UNIVERSITY   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Genetic polymorphisms; RAS; Renal transplantation; TGF

Indexed keywords

ANGIOTENSIN II; ARGININE; CYCLOSPORIN; GELATINASE A; GELATINASE B; GENOMIC DNA; ISOLEUCINE; LEUCINE; LOSARTAN; MATRILYSIN; PROLINE; STROMELYSIN; TANOMASTAT; THREONINE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; DISEASE COURSE; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CORRELATION; GENOTYPE; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; NEPHRITIS, INTERSTITIAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77956155310     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.06.008     Document Type: Article

References (74)

1. Li C., Yang C.W. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009, 5:513-519.
2. Paul L.C. Chronic allograft nephropathy: an update. Kidney Int 1999, 56:783-793.
3. Hutchinson I.V. The role of transforming growth factor-beta in transplant rejection. Transplant Proc 1999, 31:9S-13S.
4. Campistol J.M., et al. Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant 2001, 16(Suppl 1):114-116.
5. Minguela A., et al. Implication of Th1, Th2, and Th3 cytokines in liver graft acceptance. Transplant Proc 1999, 31:519-520.
6. Viklicky O., et al. TGF-beta1 expression and chronic allograft nephropathy in protocol kidney graft biopsy. Physiol Res 2003, 52:353-360.
7. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009, 11:625-630.
8. Yuan X., et al. Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci U S A 2009, 106:10734-10739.
9. Border W.A., Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
10. Gellai M. Physiological role of endothelin in cardiovascular and renal hemodynamics: studies in animals. Curr Opin Nephrol Hypertens 1997, 6:64-68.
11. Gellai M., et al. Contribution of endogenous endothelin-1 to the maintenance of vascular tone: role of nitric oxide. Pharmacology 1997, 55:299-308.
12. Perrella M.A., et al. Suppression of interleukin-1beta-induced nitric-oxide synthase promoter/enhancer activity by transforming growth factor-beta1 in vascular smooth muscle cells. Evidence for mechanisms other than NF-kappaB. J Biol Chem 1996, 271:13776-13780.
13. Ahuja S.S., et al. Regulation of transforming growth factor-beta 1 and its receptor by cyclosporine in human T lymphocytes. Transplantation 1995, 60:718-723.
14. Khanna A., et al. In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Transplantation 1997, 63:1037-1039.
15. Wolf G., et al. Transforming growth factor beta mediates the angiotensin-II-induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells. Nephrol Dial Transplant 1996, 11:263-269.
16. Shin G.T., et al. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation 1998, 65:313-318.
17. Cuhaci B., et al. Transforming growth factor-beta levels in human allograft chronic fibrosis correlate with rate of decline in renal function. Transplantation 1999, 68:785-790.
18. Randall L.L., Hardy S.J. Unity in function in the absence of consensus in sequence: role of leader peptides in export. Science 1989, 243:1156-1159.
19. Benson S.A., Hall M.N., Silhavy T.J. Genetic analysis of protein export in Escherichia coli K12. Annu Rev Biochem 1985, 54:101-134.
20. Lyons R.M., et al. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990, 110:1361-1367.
21. Hueso M., et al. Relationship between subclinical rejection and genotype, renal messenger RNA, and plasma protein transforming growth factor-beta1 levels. Transplantation 2006, 81:1463-1466.
22. Awad M.R., et al. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998, 66:1014-1020.
23. Yamada Y., et al. Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 1998, 13:1569-1576.
24. Thakkinstian A., et al. Association between cytokine gene polymorphisms and outcomes in renal transplantation: a meta-analysis of individual patient data. Nephrol Dial Transplant 2008, 23:3017-3023.
25. Chow K.M., et al. Transforming growth factor-beta1 gene polymorphism in renal transplant recipients. Ren Fail 2005, 27:671-675.
26. Inigo P., et al. [Role of transforming growth factor beta-1 gene polymorphisms in the development of chronic allograft nephropathy in renal transplant recipients]. Nefrologia 2003, 23:312-320.
27. Nikolova P.N., et al. Cytokine gene polymorphism in kidney transplantation-impact of TGF-beta 1, TNF-alpha and IL-6 on graft outcome. Transpl Immunol 2008, 18:344-348.
28. van de Wetering J., et al. The impact of transforming growth factor-beta1 gene polymorphism on end-stage renal failure after heart transplantation. Transplantation 2006, 82:1744-1748.
29. Cheng Z.J., Vapaatalo H., Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005, 11:RA194-RA205.
30. Suzuki Y., et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003, 356:881-900.
31. Geara A.S., et al. The renin-angiotensin system: an old, newly discovered player in immunoregulation. Transplant Rev (Orlando) 2009, 23:151-158.
32. Cruzado J.M., et al. Influence of nephron mass in development of chronic renal failure after prolonged warm renal ischemia. Am J Physiol Renal Physiol 2000, 279:F259-F269.
33. Mackenzie H.S., et al. Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest 1994, 94:2148-2152.
34. Meyer T.W., et al. Reversing glomerular hypertension stabilizes established glomerular injury in renal ablation. J Hypertens Suppl 1986, 4:S239-S241.
35. Amuchastegui S.C., et al. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998, 9:1948-1955.
36. Lutz J., et al. Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy. Kidney Int 2006, 70:1080-1088.
37. Noris M., et al. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Int 2003, 64:2253-2261.
38. Noble N.A., Border W.A. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target?. Semin Nephrol 1997, 17:455-466.
39. Border W.A., Noble N.A. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998, 31:181-188.
40. Wolf G., et al. Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c-mas oncogene. Kidney Int 1995, 48:1818-1827.
41. Wolf G., et al. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993, 92:1366-1372.
42. Gibbons G.H., Pratt R.E., Dzau V.J. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992, 90:456-461.
43. Brezniceanu M.L., et al. Transforming growth factor-beta 1 stimulates angiotensinogen gene expression in kidney proximal tubular cells. Kidney Int 2006, 69:1977-1985.
44. Rigat B., et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
45. Agachan B., et al. Angiotensin converting enzyme I/D, angiotensinogen T174M-M235T and angiotensin II type 1 receptor A1166C gene polymorphisms in Turkish hypertensive patients. Exp Mol Med 2003, 35:545-549.
46. Jiang X., et al. Association between renin-angiotensin system gene polymorphism and essential hypertension: a community-based study. J Hum Hypertens 2009, 23:176-181.
47. Abdi R., et al. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation 2001, 72:726-729.
48. Barocci S., et al. Correlation between angiotensin-converting enzyme gene insertion/deletion polymorphism and kidney graft long-term outcome in pediatric recipients: a single-center analysis. Transplantation 1999, 67:534-538.
49. Rodriguez-Moreno A., et al. Association of the genetic polymorphisms of the renin-angiotensin system with kidney graft long-term outcome: preliminary results. Transplant Proc 2005, 37:3716-3717.
50. Beige J., et al. Angiotensin-converting-enzyme insertion/deletion genotype and long-term renal allograft survival. Nephrol Dial Transplant 1998, 13:735-738.
51. Biselli P.M., et al. Angiotensin-converting enzyme gene polymorphism in chronic allograft nephropathy. Transplant Proc 2006, 38:1327-1328.
52. Broekroelofs J., et al. Risk factors for long-term renal survival after renal transplantation: a role for angiotensin-converting enzyme (insertion/deletion) polymorphism?. J Am Soc Nephrol 1998, 9:2075-2081.
53. Harden P.N., et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995, 345:1540-1542.
54. Waller J.R., Nicholson M.L. Molecular mechanisms of renal allograft fibrosis. Br J Surg 2001, 88:1429-1441.
55. Chang H.R., et al. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 2006, 366:243-248.
56. Inkinen K.A., et al. Fibrosis and matrix metalloproteinases in rat renal allografts. Transpl Int 2005, 18:506-512.
57. Lutz J., et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 2005, 79:655-661.
58. Mas V., et al. Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation 2007, 83:448-457.
59. Rodrigo E., et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-2 in renal transplant recipients with chronic transplant nephropathy. Nephrol Dial Transplant 2000, 15:2041-2045.
60. Rodder S., et al. Renal allografts with IF/TA display distinct expression profiles of metzincins and related genes. Am J Transplant 2009, 9:517-526.
61. Nicholson M.L., Waller J.R., Bicknell G.R. Renal transplant fibrosis correlates with intragraft expression of tissue inhibitor of metalloproteinase messenger RNA. Br J Surg 2002, 89:933-937.
62. Cozzolino M., et al. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients. Nephrol Dial Transplant 2009, 24:2207-2212.
63. Hirakawa S., et al. Evaluation of genetic variation and association in the matrix metalloproteinase 9 (MMP9) gene in ESRD patients. Am J Kidney Dis 2003, 42:133-142.
64. Nair S., et al. Further evidence for the association of MMP9 with nephropathy in type 2 diabetes and application of DNA pooling technology to candidate gene screening. J Nephrol 2008, 21:400-405.
65. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 2000, 19:623-629.
66. Cho J.H., et al. Association of C-509T and T869C polymorphisms of transforming growth factor-beta1 gene with chronic allograft nephropathy and graft survival in Korean renal transplant recipients. Transplant Proc 2008, 40:2355-2360.
67. Melk A., et al. Cytokine single nucleotide polymorphisms and intrarenal gene expression in chronic allograft nephropathy in children. Kidney Int 2003, 64:314-320.
68. Dmitrienko S., et al. Immune response gene polymorphisms in renal transplant recipients. Transplantation 2005, 80:1773-1782.
69. Alakulppi N.S., et al. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. Transplantation 2004, 78:1422-1428.
70. Park J.Y., et al. TNF-alpha and TGF-beta1 gene polymorphisms and renal allograft rejection in Koreans. Tissue Antigens 2004, 64:660-666.
71. Akcay A., et al. Angiotensin-converting enzyme genotype is a predictive factor in the peak panel-reactive antibody response. Transplant Proc 2004, 36:35-37.
72. Reis K., et al. Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to chronic allograft dysfunction. Clin Transplant 2005, 19:10-14.
73. Hueso M., et al. Angiotensin converting enzyme genotype and chronic allograft nephropathy in protocol biopsies. J Am Soc Nephrol 2004, 15:2229-2236.
74. Prasad G.V., et al. Angiotensinogen M235T genotype predicts progression in chronic renal allograft dysfunction. Transplantation 2003, 75:209-216.